Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Sch...(elaying the time to relapse said Henry ...),Health

Date:8/3/2009

elaying the time to relapse," said Henry A. Nasrallah, M.D., a clinical investigator who worked on the INVEGA(R) SUSTENNA(TM) clinical trials, and a Professor of Psychiatry and Neuroscience and Director of the Schizophrenia Research Program at the University of Cincinnati College of Medicine. "The approval of once-monthly INVEGA(R) SUSTENNA(TM) will provide healthcare professionals with a treatment option that is, at the same time, a definitive monitoring tool for uninterrupted medication compliance, which may help optimize clinical outcomes in schizophrenia."

The approval is based on four acute symptom control studies and a longer-term maintenance study that compared INVEGA(R) SUSTENNA(TM) to placebo. INVEGA(R) SUSTENNA(TM) was superior to placebo in improving positive and negative syndrome scale (PANSS) total scores in the acute treatment trials and significantly delayed time to relapse vs. placebo in the longer-term maintenance study.

The most recent acute symptom control study was a multi-center, randomized, placebo-controlled, double-blind, parallel-group study (n=636). All patients received a dose of 234 mg on Day 1 in the deltoid muscle. From Day 8 and monthly thereafter, patients were assigned to one of three fixed doses of INVEGA(R) SUSTENNA(TM) for a period of 13 weeks. The primary endpoint of this study was the change in total PANSS score from baseline to endpoint. Each of the three additional acute treatment studies involving INVEGA(R) SUSTENNA(TM) met its primary endpoint of significantly improving PANSS scores relative to placebo.

The efficacy of INVEGA(R) SUSTENNA(TM) in maintaining symptomatic control in schizophrenia was evaluated in a multicenter, randomized, double-blind, placebo-controlled, parallel-group study (n=410). Time-to-first relapse -- the primary endpoint of the study -- was significantly longer for patients receiving INVEGA(R) SUSTENNA(TM) compared with placebo-t
'/>"/>

SOURCE Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skins Natural Moisture
2. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
3. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
4. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
5. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
6. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
7. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
8. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
9. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
10. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
11. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia